AriBio
AriBio develops and advances drug candidates to treat neurodegenerative and infectious diseases for patients worldwide. The company is a clinical-stage biotechnology and pharmaceutical developer that advances lead asset AR1001 into a global Phase 3 program while managing global clinical operations and regulatory affairs from offices in South Korea and the U.S. AriBio uses traditional biopharma development pathways—preclinical research, clinical trials, and regulatory submissions—to bring small molecules/biologic therapeutics toward approval. Category: clinical-stage biotech/pharmaceutical company. The company targets healthcare markets and patients through clinical development and regulatory commercialization channels.
AriBio
AriBio develops and advances drug candidates to treat neurodegenerative and infectious diseases for patients worldwide. The company is a clinical-stage biotechnology and pharmaceutical developer that advances lead asset AR1001 into a global Phase 3 program while managing global clinical operations and regulatory affairs from offices in South Korea and the U.S. AriBio uses traditional biopharma development pathways—preclinical research, clinical trials, and regulatory submissions—to bring small molecules/biologic therapeutics toward approval. Category: clinical-stage biotech/pharmaceutical company. The company targets healthcare markets and patients through clinical development and regulatory commercialization channels.